Содержание материала

1.    Sherman DL. Exercise and endothelial function. Coron Artery Dis. 2000;11:117-122.
2.    Hambrecht R, Wolf A, Cielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000;342:454-460.
3.    Caterina R. Endothelial dysfunctions: common denominators in vascular disease. CurrOpin Lipidol. 2000;11:9-23.
4.    Contreras F, Rivera M, Vasquez, J, et al. Endothelial dysfunction in arterial hypertension. J Hum Hypertens. 2000;14(suppl 1): S20-S25.
5.    VanHoutie PM. Howto assess endothelial function in human blood vessels. J Hypertens. 1999;17:1047-1058.
6.    Ruschitzka F, Corti R, Noll G, Luscher TF. A rationale for treatment of endothelial dysfunction in hypertension. J Hypertens. 1999; 17 (suppl):S25-S35.
7.    Danza JA, Cardillo C. Potential mechanisms of endothelial dysfunction in patients with essential hypertension. J Hypertens. 1998; 16 (suppl 8):S43-S48.
8.    Intengan HD, Schiffrin EL. Role of endothelium in modulation of structural changes of small arteries in hypertension: effects of therapeutic intervention. J Hypertens. 1998:16 (suppl 8):S97-S101.
9.    John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hyp-erlipidemia: potential mechanisms and differences. J Hypertens. 2000,18:363-374.
10.    ChunTH, Itoh H, SaitoT, etal. Oxidative stress augments secretion of endothelium-derived relaxing peptides, С-type natriuretic peptide and adrenomedullin. J Hypertens. 2000;18:S7S-S80.
11.    Adams MR, Kinlay S, Blake J, et al. Atherogenic lipids and endothelial dysfunction: mechanisms in the genesis of ischemic syndromes. Annu Rev Med. 2000;51:149-167.
12.    MclntyreM, BohrDF, Dominiczak AF. Endothelial function in hypertension. The role of superoxide anion. Hypertension. 1999;34:539-545.
13.    PepineCJ. Clinical implications of endothelial dysfunction. Clin Cardiol. 1998;-21:795-799.
14.    Anderson TJ, Meredith IT, Charbonneau F. Endothelium-dependent coronary vaso-motion relates to the susceptibility of LDL to oxidation in humans. Circulation. 1996; 93:16471650.
15.    Pedrinelli R, DeN’omoC, BandinelliS, etal. Transvascularalbumin leakage and forearm vasodilation to acetylcholine in essential hypertension. Am J Hypertens. 2000;13:256-261.
16.    KlobS, BoulournieA, Mulsch A. Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. Hypertension. 2000;35:43-47.
17.    Blankenship KA, Dawson CB, Aronoff CR, Dean WL. Tyrosine phosphorylation of human platelet plasma membrane CA2*-atpase in hypertension. Hypertension. 2000;35:103-107.
18.    Suuaidi JA, Hamasaki S, Higano ST, et al. Long-term followup of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000,101:948-954.
19. Celermajer DS. Howto measure endothelial functions in humans. Cardiol Rev. |999;DEC:1-7.
20.    Yamakawa T, TanakaS, Numaguchi К, etal. Involvement of rho-kinase in Angiotensin
II    induced hypertrophy of rat vascular smooth muscle cells. Hypertension. 2000;35[-part 2J :313-318.
21.    HankeCJ, O’Brien T, Pitchard KAetal. Inhibition of adrenal cell aldosterone synthesis by endogenous nitric oxide release. Hypertension. 2000;35[part2]:324-328.
22.    Jackson WF. Ion channels and vascular tone. Hypertension. 2000;35[part 2]:173-178.
23.    Smith IA, Lew RA, Shrimpton CN. A novel stable inhibitor of endopeptidases EC3.4.24.15 and potentiates bradykinin-induced hypertension. Hypertension. 2000;35:626-630.
24.    ParissisJT, Venetsanou, KF, Kalantzi MV. Serum profiles of Granulocyte- Macrophage colony stimulating factor and CC chemokines in hypertensive patients with or without significant hyperlipidemia. Am J Cardiol. 2000;85:777-779.
25.    PezzaV, Bernardini F, Pezza E, etal. Study of supplemental oral L-arginine in hypertensives treated with enalapril plus hydrochlorothiazide. Am J Hypertens. 1998;Vol ll(No.10)Part 1:1267-1269.
26.    Watanabe C, Tomiyama H, Doba N. Effects of oral administration of L-arginine on renal function in patients with heart failure. J Hypertens. 2000; 18:229-234.
27.    Lind L, Granstam S, MillgardJ. Endothelium-dependent vasodilation in hypertension: a review. Blood Pressure. 2000;9:4-15.
28.    GoonasekeraCDA, Shah V, Rees DD, Dillon MJ. Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma? Blood Press. 2000;9: 16-21.
29.    Caterina RD, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2000;71(suppl):213S-223S.
30.    Cotton S, Vadala A, Mangano MT, et al. Endothelium derived factors in microalbu-minuric and nonmicroalbuminuric essential hypertension. Am J Hypertens. 2000,13:172- 176.
31.    Kobayashi N, Нага K, Watanade S, et al. Effect of imidapril on myocardial remodeling in L-name induced hypertensive rats is associated with gene expression of NOS and ACEmRNA. Am J Hypertension. 2000;13:199-207.
32.    Hayashi S, Morishita R, Matsushita H. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells accompanied by induction of P53 and P21. Hypertension. 2000;35[part 21:237-243.
33.    Gros R, Chorazyczewski J, Meek M. G-protein-coupled receptor kinase activity in hypertension. Hypertension. 2000;35:38-42.
34.    Dendorfer A, Wolfrum S, Schafer U, etal. Potentiation of the vascular response to kinins by inhibition of myocardial kininases. Hypertension. 2000;35:32-37.
35.    Haller H, Kettritz R, Luft F. Endothelial cell markers in vasculitis. Kidney Blood Press Res. 1998;21:280-282.
36.    Meerarani P, Ramadass P, Toborek M. Zinc protects against apoptosis of endothelial cells induced by linoleic acid and tumor necrosis factor. Am J Clin Nutr. 2000;71:81-
37.    Riser BL, Cortes P, Lee J. Modelling the effects of vascular stress in mesangial cells. CurrOpin Nephrol Hypertens. 2000;9:43-47.
38.    Petruzzelli L, Takami M, Humes D. Structure and function of cell adhesion molecules. Am) Med. 1999;106:467-476.
39.    Etzioni A. Integrins: the molecular glue of life. Hosp. Pract. 2000;March 15:102-111.
40.    Marul N, Offermann MK, Swerlicis R. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993,92:1866-1874.
41.    Price DT, Loscalzo ]. Cellular adhesion molecules and atherogenesis. Am) Med. 1999;107:85-97.
42.    Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults. Implications for prevention from the pathobiologi-cal determinants of atherosclerosis in youth study. JAMA. 1999;281:727-735.
43.    EnosWF, Holmes RH, Beyer T. Coronary disease among United States soldiers killed in action in Korea [landmarkarticle]. JAMA. 1986;256:2859-2862.
44.    Assman C, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Eur Heart J. 1998;19(suppl A):A2-A11.
45.    Holman RL, McCill HC, Strong JP, Ceer JC. The natural history of atherosclerosis Am J Pathol. 1958;34:209-235.
46.    Stewart KG, Zhang Y, Davidge S. Aging increases PCHS-2-dependent vasoconstriction in rat mesenteric arteries. Hypertension. 2000;35:1242-1247.
47.    Chester AH, Boriand JAA. Chymase-dependent angiotensin II formation in human bloodvessels. J Hum Hypertens. 2000;14:373-376.
48.    McCord JM. The evolution offree radicals and oxidative stress. AmJ Med. 2000;1-08:652-659.
49.    Dhalla NS, Temsah RM, Netticadan T. The role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18:655-673.
50.    Wolf C. Free radical production and angiotensin. Curr Hypertens Reports. 2000;2:167-173.
51.    Somers MT, Harrison DC. Reactive oxygen species and the control of vasomotor tone. Curr Hypertens Reports. 1999;1:102-108.
52.    Usui M; Egashira K, Kitamoto S, et al. Pathogenic role of oxidative stress in vascular angiotensin converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension. 1999;34:546-551.
53.    Laakso J, Mervaala E, Himberg JJ, et al. Increased kidney xantine oxidoreductase activity in salt-induced experimental hypertension. Hypertension. 1998;32:902906.
54.    Romero JC, Reckelhoff JF Role of angiotensin and oxidative stress in essential hypertension. Hypertensin. 1999;34(part 2):943-949
55.    Pedro-Botet J, Covas Ml, Martin S, Rubies-PratT. Decreased endogenous antioxidant enzymatic status in essential hypertension. J Hum Hypertens. 2000;14:343-345
56.    Greene EL, Verlarde V, Jaffa AA. Role of reactive oxygen species in bradykinin-induc-ed mitogen-activated protein kinase and C-FOS induction in vascular cells. Hypertension. 2000;35:942-947.
57.    Ma GE, Mason DP, Young DB Inhibition of vascular smooth muscle cell migration by elevation of extracellular potassium concentration. Hypertension. 2000;35:948-951.
58.    Lu G, Green L, Nagai T, Egan BM. Reactive oxygen species are critical in the oleic acid-mediated mitogenic signaling pathway in vascular smooth muscle cells. Hypertension. 1998;32:1003-1010.
59.    Orie N, Zidek W, Tepel M. Reactive oxygen species in essential hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens. 1999; 12:1169-1174.
60.    Koska J, Syrova D, Blazicek P, et al. Malondialdehyde, lipofuscin and activity of antioxidant enzymes during physical exercise in patients with essential hypertension.
J Hypertens. 1999;17:529-S35.
61.    ManciniGBJ, Henry GC, MacayaC. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 1996;94:258-265.
62.    Anderson TJ, Overhiser RW, Haber H, Charbonneau F, etal. A comparative study of four antihypertensive agents on endothelial function in patients with coronary disease [abstract]. J Am Coll Cardiol. 1998;31:327A.
63.    Hornig B, Arakawa N, Haussman D, Drexler H. Differential effects on quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 1998;98:2842-2848.
64.    Oosterga M, Voors AA, Buikema H. Functional effects of ACE-inhibitors on angiotensin I conversion in human vasculature. J Am Coll Cardiol. 1998;31 (suppl A):239A.
65.    Fabre J-E, Rivard A, Magnin M, Isner JM. Angiotensin converting enzyme inhibition with quinaprilat stimulates angiogenesis in a rabbit model with hindlimb ischemia [abstract]. J Am Coll Cardiol. 1998;31 (suppl A):239A.
66.    Nissen SE, Gurley JC, Booth DC, DeMariaAN. Intravascular ultrasound of the coronary arteries: current applications and future directions. Am J Cardiol. 1992;69:18H-29H.
67.    Pepine CJ. A symposium: endothelial function and cardiovascular disease: potential mechanisms and interventions. Am J Cardiol. 1998;82(10A):1S-64S.
68.    Weir MR, Henrich WL. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin in Nephrol and Hypertens. 2000;9:403-411.
69.    Cohn )N. ACE-inhibition and vascular remodeling of resistance vessels. Vascular compliance and cardiovascular implications. Heart Disease. 2000;2:S2-S6.
70.    Cohn JN. Vascular wall function as a risk marker for cardiovascular disease. J Hypertens. 1999; 17(suppl S):S41 -S44.
71.    McVeigh GE, Bratteli CW, Morgan DT, etal. Age related abnormalities in arterial compliance identified by pressure pulse contour analysis. Aging and arterial compliance. Hypertension. 1999;33(6): 1392-1398.
72.    Vlachopoulos C, O’Rourke M. Diastolic pressure, systolic pressure or pulse pressure? Curr Hypertens Reports. 2000;2:271-279.
73.    Glaser SP, Arnett DK, McVeigh GE, et al. Vascular compliance and cardiovascular disease. A risk or a marker? Am J Hypertens. 1997; 10:1175-1189.
74.    Glasser SP, Arnett DK, McVeigh GE, et al. The importance of arterial compliance in cardiovascular drug therapy. J Clin Pharmacol. 1998;38:202-212.
75.    ParkJB, Schiffrin EL. Effects of Antihypertensive therapy on hypertensive vascular disease. Curr Hypertens Reports. 2000;2:280-288.
76.    Franklin SS. Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance? Current Hypertens Reps. 2000;2:253-259.
77.    Buemi M, Corica F, Marino D, etal. Cardiovascular remodeling, apoptosisand drugs. Am) Hypertens. 2000;13:450-454.
78.    Cohn J. Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease. Prog Cardiovasc Dis. 1999;41(6):441-450.
79.    O’Rourke MF. Isolated systolic hypertension, pulse pressure and arterial stiffness as risk factors for cardiovascular disease. Curr Hypertens Rep. 1999;3:204-211.
80.    Bulpitt C), Cameron JD, Rajkumar C. The effects of age on vascular compliance in man: which are the appropriate measures? J Hum Hypertens. 1999; 13:753-758.
81.    Sharifi AM, Schiffrin EL. Apoptosis in vasculature of spontaneously hypertensive rats. Effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. Am I Hypertens. 1998;11:1108-1116.
82.    Bank A), Kaiser DR. Smooth muscle relaxation. Effects on arterial compliance, Dis-tensibility, elastic module and pulse wave velocity. Hypertension. 1998;32:356-359.
83.    Arnett DK, Boland LL, Evans GW, et al. Hypertension and arterial stiffness: the atherosclerosis risk in communities study. Am J Hypertens. 2000;13:317-323
84.    Cockeroft JR, Webb D), Wilkinson IB. Arterial stiffness, hypertension and diabetes mellitus. J Hum Hypertens. 2000;14:377-380.
85.    Franklin SS. Aging and hypertension: the assessment of blood pressure indices in predicting coronary heart disease.) Hypertens. 1999,17(suppl 5):S29-S36.
86.    Baumbach CL, Chillon JM. Effects of angiotensin-converting enzyme inhibitors on cerebral vascular structure in chronic hypertension. J Hypertens. 2000; 18(suppl): S7-S11.
87.    Kuller LH, Sutton-Tyrrell K, Matthews KA. Blood pressure levels and measurement of Subclinical vascular disease. J Hypertens. 1999; 17(suppl 5):S15-SI9.
88.    MalekAM, AlperSL, IzumoS. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282(21):2035-2042.
89.    Resnick N, Yahau H, SchubertS, etal. Signaling pathways in vascular endothelium activated by shear stress: relevance to atherosclerosis. CurrOpin in Lipidol. 2000; 11:167177.
90.    Kannel WB. Elevated blood pressure as a cardiovascular risk factor. Am J Cardiol. 2000;85:251-255.
91.    Smulyan H, Safar ME. The diastolic blood pressure in systolic hypertension. Ann Intern Med. 2000;132;233-237.
92.    Staessen JA, Gasowski J, Wang JC, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865-872.
93.    Starmans-Kool, MJF, Kleinjans, HAJ, Lustermans, FAT, etal. Treatment of elderly patients with isolated systolic hypertension with isosorbide dinitrate in an asymmetric dosing schedule. J Hum Hypertens. 1998;12:557-561.
94.    Black HR, Kuller LH, O’Rourke MF, etal. The first report of the systolic and pulse pressure (SYPP) working group. ] Hypertens. 1999; 1 7(suppl5):S3-S14.
95.    Blacher J, Staessen JA, Cirerd X, et al. Pu Ise pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med. 2000;160:1085-1089.
96.    Safar ME. Epidemiological aspects of pulse pressure and arterial stiffness. J Hypertens. 1999; 17(suppl 5):S37-S40.
97.    Busse R, Fleming I. Nitric oxide, nitric oxide synthase, and hypertensive vascular disease. Curr Hypertens Reports. 1999;1:85-88.
98.    StamlerJ. Nitric oxide in the cardiovascular system. Coron Artery Dis. 1999; 10:273-276.
99.    Soma M, Nakayama T, Kanmatsuse К. N itric oxide synthase gene polymorphism and its influence on cardiovascular disease. CurrOpin Nephrol Hypertens. 1999;8:83-87.
100.    Maxwell AJ, Cooke JP. The role of nitric oxide in atherosclerosis. Coron Artery Dis. 1999;10:277-286.
101.    Zou AP, Cowley AW. Role of nitric oxide in the control of renal function an salt sensitivity. Curr Hypertens Reports. 1999; 1:178-186.
102.    Klahr S. The role of L-arginine in hypertension and nephrotoxicity. Opin Nephrol Hypertens. 1998;7:547-550.
103.    Bhagat K, Vallance P. Effects of cytokines on nitric oxide pathways in human vasculature. Current Opinion in Nephrology and Hypertension. 1999;8:89-96.
104.    Campbell DJ. Bioactive angiotensin peptides other than angiotensin II receptor antagonists. Epstein M, and Brunner HR (eds): Angiotension II ReceptorAnt-agonists. Hanley and Belfus, Philadelphia, 2001.
105.    Gimbrone MA, Topper JN. Biology of the vessel wall: endothelium. In Chien KR (ed): Molecular Basis of Cardiovascular Disease. Philadelphia, WB Saunders Company, 1999, pp 331-348.
106.    Libby P, Hansson GK, Rober JS. Atherogenesis and inflammation. In Chien KR (ed): Molecular Basis of Cardiovascular Disease. Philadelphia, WB Saunders, 1999, pp 349-366.
107.    PanzaJA. Nitricoxide in hypertension, pp 158-165. InOparil S, Weber MA (eds): Hypertension: A Companion to Brenner and Rector’s: The Kidney. Philadelphia, WB Saunders, 2000, pp 158-165.
108.    Oparil S, Weber MA. Hypertension: A Companion to Brenner and Rector’s: The Kidney. Philadelphia, WB Saunders, 2000.
109.    Fabiani ME, Dinh DT, Nassis L, Johnston Cl. Angiotensin-converting enzyme: basic properties, distribution and functional role. In Weber MA (eds): Hypertension: A Companion to Brenner and Rector’s: The Kidney. WB Saunders, 2000, pp 90-97.
110.    Stary HC. Atlas of Atherosclerosis: Progression and Regression. New York and London, Parthenon, 1999.
111.    Kannel WB, Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1 572-1 576.
112.    Weber MA, Smith DHC, Neutel JM, CraettingerWF. Arterial properties of early hypertension. J Hum Hypertens. 1991;5:417-423.
113.    Dzau VJ, Gibbons GH. Vascular remodeling: mechanisms and implications. J Cardiov-asc Pharmacol. 1993;21 (suppl 1):S1-S5.
114.    Dzau, VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153:937-942.